Head-to-Head

Creative Medical Technology Holdings, Inc. Common Stock vs. Halozyme Therapeutics, Inc.

CELZ

Creative Medical Technology Holdings, Inc. Common Stock

$0.93 -3.17%

VS HALO

Halozyme Therapeutics, Inc.

$110.40 -1.04%

Creative Medical Technology Holdings, Inc. Common Stock and Halozyme Therapeutics, Inc. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.

Size & Scale

CELZHALO
Market Cap $7.10 million $12.66 billion
Revenue (TTM) — $1.66 billion
Net Income (TTM) — $413.60 million

HALO leads on 1 of 1 size & scale factors.

Valuation

CELZHALO
P/E Ratio — 32.28
Price / Book — 88.21
Price / Sales — 7.61

CELZ and HALO split the valuation factors evenly.

Profitability

CELZHALO
Net Margin — 24.86%
Return on Equity — 288.13%

CELZ and HALO split the profitability factors evenly.

Risk & Sentiment

CELZHALO
Short Interest 0.18% 9.79%

CELZ leads on 1 of 1 risk & sentiment factors.

Dig deeper: CELZ overview, CELZ financials, HALO overview, HALO financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.